Cognition Therapeutics 2025 net loss narrows as expenses fall

Reuters03-26
Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 2025 net loss narrows as expenses fall

Overview

  • US biopharmaceutical firm's 2025 net loss narrowed as operating expenses declined

  • Company ended 2025 with $37 mln in cash, plus $35.7 mln in obligated grant funds

  • Company expects cash to fund operations through Q2 2027

Outlook

  • Company expects FDA meeting on DLB psychosis clinical plan by mid-2026

  • Company estimates cash sufficient to fund operations through Q2 2027

Result Drivers

  • LOWER R&D SPENDING - Research and development expenses fell due to completion of SHINE and SHIMMER clinical trials and associated professional fees

  • INCREASED GRANT INCOME - Higher grant income from the National Institute of Aging and related sources helped offset losses

Company press release: ID:nGNXbfdT9q

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Net Income

-$23.49 mln

FY Income From Operations

-$47.80 mln

FY Operating Expenses

$47.80 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 215.3% above its March 25 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment